Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD

At the 72nd annual American College of Cardiology (ACC) meeting, new real-world data was presented from the XARENO study demonstrating that the new oral anticoagulant (NOAC) Xarelto (rivaroxaban) was associated with a reduced risk of adverse kidney outcomes in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKAs) (abstract #1102-004). AF patients with advanced CKD represent a significant yet underserved subgroup of the AF population. With the potential safety benefits of rivaroxaban compared to VKAs, as demonstrated in the XARENO study, GlobalData predicts that this therapy could become a crucial new treatment option for the many AF patients with advanced CKD.